-
Peroxidasin Drives GBM Glycolysis via LDHA: Mechanistic Insi
2026-05-24
This study identifies Peroxidasin (PXDN) as a key regulator of glycolytic metabolism in glioblastoma (GBM) by modulating LDHA expression. Robust experimental evidence demonstrates that PXDN promotes malignant progression, suggesting new biomarker and therapeutic avenues for GBM management.
-
D-Luciferin Potassium Salt: Optimizing In Vivo Imaging Workf
2026-05-23
D-Luciferin (potassium salt) empowers researchers with unmatched sensitivity and reproducibility for real-time in vivo bioluminescence imaging and luciferase-based assays. This article details protocol enhancements, troubleshooting strategies, and translational insights—bridging recent discoveries in tumor immune surveillance with robust experimental workflows.
-
TECPR1-Driven Lysosomal Repair Under Energy Stress: New Mech
2026-05-22
The referenced study uncovers TECPR1 as a pivotal mediator of lysosomal membrane repair during energy crisis, acting through PI4P recognition and KIF1A-driven membrane tubulation. These insights advance our understanding of cellular adaptation to metabolic stress and have important implications for research on lysosome-related diseases.
-
Forsythoside E: PKM2 Inhibitor for Macrophage Polarization
2026-05-22
Forsythoside E is a phenolic acid glycoside that serves as a selective pyruvate kinase M2 (PKM2) inhibitor and macrophage M2 polarization inducer. It alleviates sepsis-induced liver injury by promoting PKM2 tetramerization, suppressing STAT3 phosphorylation, and inhibiting macrophage glycolysis. These properties make it a valuable tool for immunometabolic research in sepsis models.
-
Glioma Stem Cell Membrane-Coated Nanozymes for Dual-Targeted
2026-05-21
This study introduces a glioma stem cell membrane-camouflaged photothermal nanozyme system that enables dual-targeted drug delivery across the blood-brain barrier for improved glioblastoma multiforme (GBM) therapy. The work demonstrates synergistic antitumor effects via combined chemotherapeutic, chemodynamic, and photothermal modalities, achieving significant tumor suppression and extended survival in animal models.
-
Chloroquine for Autophagy and Disease Research: Protocols &
2026-05-21
Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) delivers reproducible autophagy inhibition and multi-targeted modulation for malaria, cancer, and autoimmune research. This guide translates recent mechanistic insights into actionable workflows and troubleshooting strategies for maximizing Chloroquine’s experimental impact.
-
Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod
2026-05-20
This study systematically characterizes the pharmacokinetic variability and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in the context of metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight disease-induced alterations in drug disposition, mediated by changes in metabolic enzymes and transporters, providing critical guidance for future therapeutic strategies in chronic liver disease.
-
AM 281: Advancing CB1 Cannabinoid Receptor Antagonist Resear
2026-05-20
AM 281 is a potent, selective CB1 cannabinoid receptor antagonist that enables precise dissection of endocannabinoid signaling in neuropharmacology models. Its unique properties empower researchers to probe cognitive dysfunction, neuroprotection, and memory impairment strategies with greater clarity and reproducibility.
-
BRD4 Inhibition Sensitizes Tumors to Ferroptosis via TXNIP a
2026-05-19
This study uncovers how BET bromodomain inhibitor (+)-JQ1 enhances ferroptosis sensitivity in solid tumor cells by upregulating TXNIP and suppressing histone H4 UFMylation. The findings offer a mechanistic rationale to combine BRD4 inhibition with ferroptosis inducers for improved cancer therapy.
-
Trichostatin A (TSA) in Epigenetic Cancer Research Workflows
2026-05-19
Trichostatin A (TSA) is redefining the landscape of epigenetic regulation and cancer research with its robust HDAC inhibition and reproducibility in cell-based assays. This article delivers actionable workflows, troubleshooting strategies, and context from recent mitochondrial calcium signaling findings to empower precise experimental design.
-
Disulfiram: Proteasome Inhibitor and Pyroptosis Modulator in
2026-05-18
Explore how Disulfiram, a potent dopamine β-hydroxylase inhibitor, is revolutionizing cancer research through dual proteasome inhibition and pyroptosis modulation. This analysis uniquely connects mechanistic insights with practical protocols and the latest reference breakthroughs.
-
Digoxin in Translational Research: Precision Cardiac and Ant
2026-05-18
Explore how Digoxin, a potent Na+/K+ ATPase pump inhibitor, is redefining both arrhythmia treatment research and antiviral assay design. This article delivers deep insight into cross-domain applications, technical protocols, and evidence-based limitations.
-
Thiamet G: O-GlcNAcase Inhibitor Workflows for Disease Model
2026-05-17
Thiamet G, a potent and selective O-GlcNAcase inhibitor from APExBIO, empowers researchers to finely tune O-GlcNAcylation in neurodegenerative, oncologic, and bone disease models. This article details evidence-based experimental workflows, advanced use-cases, and expert troubleshooting to get the most from your Thiamet G studies.
-
Liproxstatin-1 HCl: Precision Ferroptosis Inhibition in Rena
2026-05-16
Liproxstatin-1 HCl offers robust, nanomolar-potency inhibition of ferroptosis, making it indispensable for acute renal failure and hepatic ischemia/reperfusion injury research. Its selectivity and reproducibility empower researchers to dissect lipid peroxidation-driven cell death with unmatched clarity.
-
VER 155008, HSP 70 Inhibitor: Reliable Tool for Apoptosis As
2026-05-15
This article provides an evidence-based guide to deploying VER 155008, HSP 70 inhibitor, adenosine-derived (SKU A4387) in cell viability, apoptosis, and cancer proliferation studies. Drawing on recent literature and quantitative data, it demonstrates how SKU A4387 offers reproducibility, workflow clarity, and robust mechanistic insight for biomedical researchers. Practical Q&As address assay design, data interpretation, and vendor selection in the context of chaperone inhibition.